AUSTIN, TX, October 01, 2020 /24-7PressRelease/ — SelenBio, Inc. is an Austin, TX based biotechnology company specializing in the formulation of SELDOX®, a patented selenium-based antimicrobial compound. The compound is proven effective in the prevention of bacteria colonization, biofilm formation, virus replication, and fungus reproduction across medical, dental, consumer and industrial applications.
Formulate, manufacture, and sell to selective licensee’s a patented selenium-based compound called SELDOX®. SELDOX, which is antibacterial, antiviral and antifungal, can be formulated and used as a coating, gel or spray or it can be integrated into material during the manufacturing process creating an antimicrobial/antiviral/antifungal characteristic that is present for the lifetime of the product.
The OCMX™ is pleased to announce the listing of SelenBio Inc. to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.
The OCMX™ has spent considerable time completing its due diligence on SelenBio Inc. and concluded that there is indeed a tremendous potential for this opportunity.
The OCMX™ noted that SelenBio Inc. exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.
1. A patented compound based upon the naturally occurring selenium element.
2. Proven safe, non-toxic, and more cost-effective than other antimicrobial compounds like silver, copper and triclosan currently on the market.
3. An innovative, disruptive, and multifunctional compound during the public’s heightened awareness of the harm caused by bacteria, viruses, and fungus, especially during the COVID-19 pandemic.
4. Platform Based Instead of Single Product: The countless number of applications that can benefit from an antimicrobial enhancement mitigates the investment risk.
Kenny Gallagher, CEO
30 years of startup, growth, and C-level executive management experience. High business acumen, detail-oriented, and analytical with strength in strategic planning combined with the ability to design, create, and deploy solutions to meet company-wide business objectives.
Karl Doenges, JD, President
15 years executive management experience in startups, SME’s, and corporations. 9 years in biotech new product commercialization and 20 years’ experience in government, regulatory, and international affairs.
Matt Belsole, Director of Business Development
15 years’ experience in sales management and strategy for healthcare and medical device products. 7 years previous experience working with SelenBio’s CEO in developing and sustaining business relationships with strategic partners and distributor accounts.
Robert Hanes, PhD, Director of Chemical Services at Sparx Engineering—Lead chemist in SELDOX® development. Expert in selenium chemistry and the use of selenium in creating antimicrobial compounds.
ABOUT THE OCMX™
The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Email: [email protected]
# # #